Form 4: IO Biotech CFO Amy Sullivan Acquires Shares in Open Market Transaction

IO Biotech's Chief Financial Officer, Amy Sullivan, purchased 10,250 shares of common stock at a weighted average price of $0.8276 per share.

Summary

• Amy Sullivan, the Chief Financial Officer of IO Biotech, Inc., acquired 10,250 shares of the company's common stock on December 23, 2024.
• The shares were purchased in multiple trades at prices ranging from $0.7861 to $0.90 per share.
• The weighted average purchase price was $0.8276 per share.
• Following the transaction, Ms. Sullivan directly owns 84,632 shares of IO Biotech common stock.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment, as it reports a routine insider transaction. The purchase could be seen as a positive sign, but it's not a major event.

Positives

• The purchase of shares by a company executive can be seen as a positive sign of confidence in the company's future prospects.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who trade their company's stock. It provides transparency into the trading activities of company executives.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the United States, ensuring transparency of insider trading activities.
• The reported transaction is typical for executives who are granted stock options or who purchase shares in the open market.

Stakeholder Impact

• The share purchase by the CFO may be viewed positively by shareholders, indicating confidence in the company's prospects.

Key Dates

Keywords

IO Biotech, insider trading, Form 4, Amy Sullivan, share purchase, CFO, stock acquisition